Adrecizumab

DRUG7 trials

Conditions

Acute Heart FailureCardiogenic ShockEndothelial DysfunctionExperimentele endotoxemie SepsisHealthy VolunteersOrgaandisfunctie blood poisoning - sepsisSeptic Shock

Phase 1

Adrecizumab Phase 1 Trial

CompletedNCT02991508

Radboud University Medical CenterHealthy Volunteers

Start: 2016-05-23End: 2016-09-22Updated: 2017-03-15

Adrecizumab-LPS Study

CompletedNCT03083171

Adrenomed AGHealthy Volunteers

Start: 2017-01-04End: 2017-05-24Updated: 2021-02-01

Phase 2

Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB

CompletedNCT03085758

Adrenomed AGSeptic Shock

Start: 2017-12-12End: 2019-12-20Updated: 2024-02-21

Adrecizumab in Cardiogenic Shock

CompletedNCT03989531

Dr. med. Mahir KarakasCardiogenic Shock, Endothelial Dysfunction

Start: 2019-04-04End: 2021-04-26Updated: 2021-10-08

A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Proof of Concept and Dose-Finding Phase II Clinical Trial to Investigate the Safety, Tolerability and Efficacy of ADRECIZUMAB in Patients with Septic Shock and Elevated Adrenomedullin

Active, not recruitingNL-OMON48885

Adrenomed AGOrgaandisfunctie blood poisoning - sepsis

Start: 2018-03-27Target: 50Updated: 2024-02-28

Adrecizumab Dose Escalation Safety and Tolerability Evaluation (ADESTE)

NCT04252937

GREAT Network ItalyAcute Heart Failure

Start: 2019-12-15End: 2022-03-31Target: 30Updated: 2021-03-09

Unknown Phase

A randomized double-blind placebo-controlled phase I study on the safety, tolerability and pharmacokinetics/-dynamics of escalating single intravenous doses of ADRECIZUMAB (HAM8101) in healthy male subjects during experimental endotoxemia.

Active, not recruitingNL-OMON43006

Adrenomed AGExperimentele endotoxemie Sepsis

Start: 2017-01-04Target: 24Updated: 2024-02-28

Related Papers

Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial.

2021-12-0828 citations

Adrecizumab: an investigational agent for the biomarker-guided treatment of sepsis.

2020-12-2113 citations

A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)

BMJ Open2019-02-0146 citations

Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study.

2018-12-2180 citations